Antiretroviral therapy: Current drugs

Infectious Disease Clinics of North America

Volumn 28, Issue 3, 2014, Pages 371-402

  Pau, Alice K ^a   George, Jomy M ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Antiretroviral therapy; CCR5 antagonist; Fusion inhibitor; HIV; Integrase strand transfer inhibitors; Non nucleoside reverse transcriptase inhibitors; Nucleoside nucleotide reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS RILPIVIRINE; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; INTEGRASE STRAND TRANSFER INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

BEDTIME DOSAGE; BONE DENSITY; CARDIOMYOPATHY; CHOLELITHIASIS; COLLAPSE; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATTY LIVER; FEVER; FLU LIKE SYNDROME; FULMINANT HEPATIC FAILURE; GASTROINTESTINAL SYMPTOM; GLUCOSURIA; HALLUCINATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INCIDENCE; INSOMNIA; INSULIN RESISTANCE; JAUNDICE; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIFE CYCLE STAGE; LIPOATROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MACROCYTIC ANEMIA; MANIA; MEDICATION COMPLIANCE; MYOPATHY; NAIL PIGMENTATION; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PANCREATITIS; PATIENT COMPLIANCE; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SKIN DISCOLORATION; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SURVIVAL; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS TRANSMISSION; VIVID DREAM; VOMITING; ADVERSE EFFECTS; DRUG DEVELOPMENT; HISTORY; HIV INFECTIONS; PROCEDURES; TRENDS;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS;

EID: 84906216720     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.06.001     Document Type: Review

References (61)

1. Fischl M.A., Richman D.D., Grieco M.H., et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. NEngl J Med 1987, 317:185-191.
2. Lederman M.M., Connick E., Landay A., et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trials group protocol 315. JInfect Dis 1998, 178:70-79.
3. Cattelan A.M., Calabro M.L., Gasperini P., et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. JNatl Cancer Inst Monogr 2001, 28:44-49.
4. De Luca A., Giancola M.L., Ammassari A., et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. The Journal of infectious diseases 2000, 182:1077-1083.
5. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. NEngl J Med 1998, 338:853-860.
6. Davey R.T., Bhat N., Yoder C., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999, 96:15109-15114.
7. HIV replication cycle. 2012. Available at:. Accessed March 10, 2014. http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/pages/hivreplicationcycle.aspx.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2013. Available at:. Accessed March 10, 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
9. Nolan D., Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004, 9:849-863.
10. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005, 10(Suppl 2):M47-M52.
11. Food and Drug Administration. Ziagen (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020977s026,020978s030lbl.pdf.
12. Gulick R.M., Ribaudo H.J., Shikuma C.M., et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. NEngl J Med 2004, 350:1850-1861.
13. Hetherington S., McGuirk S., Powell G., et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001, 23:1603-1614.
14. Frissen P.H., de Vries J., Weigel H.M., et al. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS 2001, 15:289.
15. Walensky R.P., Goldberg J.H., Daily J.P. Anaphylaxis after rechallenge with abacavir. AIDS 1999, 13:999-1000.
16. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to abacavir. NEngl J Med 2008, 358:568-579.
17. Saag M., Balu R., Phillips E., et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008, 46:1111-1118.
18. Sabin C.A., Worm S.W., Weber R., et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426.
19. Ding X., Andraca-Carrera E., Cooper C., et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. JAcquir Immune Defic Syndr 2012, 61:441-447.
20. Ofotokun I., Smithson S.E., Lu C., et al. Liver enzymes elevation and immune reconstitution among treatment-naive HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 2007, 334:334-341.
21. Bellini C., Keiser O., Chave J.P., et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV cohort study. HIV Med 2009, 10:12-18.
22. Food and Drug Administration. Truvada (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021752s043lbl.pdf.
23. Hall A.M., Hendry B.M., Nitsch D., et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011, 57:773-780.
24. Morlat P., Vivot A., Vandenhende M.A., et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLos One 2013, 8:e66223.
25. Kalayjian R.C., Lau B., Mechekano R.N., et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012, 26:1907-1915.
26. Huang J.S., Hughes M.D., Riddler S.A., et al. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 2013, 14:224-234.
27. Havens P.L., Kiser J.J., Stephensen C.B., et al. Association of higher plasma vitamind binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?. Antimicrob Agents Chemother 2013, 57:5619-5628.
28. Perrot S., Aslangul E., Szwebel T., et al. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. JClin Rheumatol 2009, 15:72-74.
29. Haverkort M.E., van der Spek B.W., Lips P., et al. Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis 2011, 43:821-826.
30. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. NEngl J Med 1994, 331:1173-1180.
31. Food and Drug Administration. Sustiva (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020972s043021360s031lbl.pdf.
32. Mollan K, Smurzynski M, Na L, etal. Hazard of suicidality in patients randomly assigned to efavirenz for initial treatment of HIV-1: a cross study analysis conducted by the AIDS Clinical Trials Group (ACTG). Abs #670. ID week 2013. San Francisco (CA): 2013. PMID: 24979445.
33. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2012. Available at:. Accessed March 10, 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
34. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2013. Available at:. Accessed March 10, 2014. http://www.who.int/entity/hiv/pub/guidelines/arv2013/download/en/index.html.
35. Food and Drug Administration. Intelence (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022187s011s012s014lbl.pdf.
36. Asahchop E.L., Wainberg M.A., Oliveira M., et al. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 2013, 27:879-887.
37. Food and Drug Administration. Viramune (product label). 2014. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020636s044,020933s035lbl.pdf.
38. Food and Drug Administration. Edurant (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202022s005lbl.pdf.
39. Nelson M.R., Elion R.A., Cohen C.J., et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies. HIV Clin Trials 2013, 14:81-91.
40. Food and Drug Administration. Reyataz (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021567s032s033lbl.pdf.
41. Nishijima T., Shimbo T., Komatsu H., et al. Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. JAntimicrob Chemother 2014, 69(5):1385-1389.
42. Rockwood N., Mandalia S., Bower M., et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011, 25:1671-1673.
43. Food and Drug Administration. Prezista (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021976s033_202895s010lbl.pdf.
44. Orkin C., DeJesus E., Khanlou H., et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med 2013, 14:49-59.
45. Food and Drug Administration. Kaletra (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021226s038lbl.pdf.
46. Food and Drug Administration. Invirase (product label). 2012. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020628s034-021785s011lbl.pdf.
47. Zhang X., Jordan P., Cristea L., et al. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. JClin Pharmacol 2012, 52:520-529.
48. Food and Drug Administration. Aptivus (product label). 2012. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021814s013,022292s006lbl.pdf.
49. Chan-Tack K.M., Struble K.A., Birnkrant D.B. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. AIDS Patient Care STDs 2008, 22:843-850.
50. Hicks C., Gulick R.M. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009, 48:931-939.
51. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV-infected individuals. 2013. Available at:. Accessed March 10, 2014. http://aidsinfo.nih.gov/contentfiles/upload/AdultARV_INSTIRecommendations.pdf.
52. Food and Drug Administration. Tivicay (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf.
53. Food and Drug Administration. Stribild (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203100s009lbl.pdf.
54. Food and Drug Administration. Isentress (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205786s000,022145s031,203045s009lbl.pdf.
55. Castagna A., Maggiolo F., Penco G., et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 Study. JInfect Dis 2014, [Epub ahead of print].
56. Steigbigel R.T., Cooper D.A., Kumar P.N., et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. NEngl J Med 2008, 359:339-354.
57. Lennox J.L., Dejesus E., Berger D.S., et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. JAcquir Immune Defic Syndr 2010, 55:39-48.
58. Lee F.J., Amin J., Bloch M., et al. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. JAcquir Immune Defic Syndr 2013, 62:525-533.
59. Food and Drug Administration. Selzentry (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022128s011lbl.pdf.
60. Food and Drug Administration. Fuzeon (product label). 2013. Available at:. Accessed March 10, 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021481s027lbl.pdf.
61. Johnson V.A., Calvez V., Gunthard H.F., et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013, 21:6-14.